메뉴 건너뛰기




Volumn 29, Issue 1, 2011, Pages 87-103

Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease

Author keywords

Cardiovascular disease; Coronary heart disease; Lipid lowering; Primary prevention; Secondary prevention; Statin; Stroke

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PROBUCOL; ROSUVASTATIN; SIMVASTATIN;

EID: 78751616628     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.10.002     Document Type: Review
Times cited : (34)

References (75)
  • 2
    • 77649091020 scopus 로고    scopus 로고
    • Executive summary: heart disease and stroke statistics-2010 update: a report from the american heart association
    • American Heart Association Statistics Committee and Stroke Statistics Subcommittee
    • Lloyd-Jones D., Adams R.J., Brown T.M., et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the american heart association. Circulation 2010, 121(7):948-954. American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
    • (2010) Circulation , vol.121 , Issue.7 , pp. 948-954
    • Lloyd-Jones, D.1    Adams, R.J.2    Brown, T.M.3
  • 3
    • 2542460047 scopus 로고    scopus 로고
    • The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL
    • Navab M., Ananthramaiah G.M., Reddy S.T., et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004, 45(6):993-1007.
    • (2004) J Lipid Res , vol.45 , Issue.6 , pp. 993-1007
    • Navab, M.1    Ananthramaiah, G.M.2    Reddy, S.T.3
  • 4
    • 0035818556 scopus 로고    scopus 로고
    • Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I
    • Shah P.K., Kaul S., Nilsson J., et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001, 104:2376-2383.
    • (2001) Circulation , vol.104 , pp. 2376-2383
    • Shah, P.K.1    Kaul, S.2    Nilsson, J.3
  • 5
    • 24944513945 scopus 로고    scopus 로고
    • Atherothrombosis and high-risk plaque: part I: evolving concepts
    • Fuster V., Moreno P.R., Fayad Z.A., et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005, 46(6):937-954.
    • (2005) J Am Coll Cardiol , vol.46 , Issue.6 , pp. 937-954
    • Fuster, V.1    Moreno, P.R.2    Fayad, Z.A.3
  • 6
    • 0000356425 scopus 로고
    • Blood lipids and human atherosclerosis
    • Gofman J.W., Jones H.B., Lindgren F.T., et al. Blood lipids and human atherosclerosis. Circulation 1950, 2(2):161-178.
    • (1950) Circulation , vol.2 , Issue.2 , pp. 161-178
    • Gofman, J.W.1    Jones, H.B.2    Lindgren, F.T.3
  • 7
    • 50449152044 scopus 로고
    • Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions
    • Barr D.P., Russ E.M., Eder H.A. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med 1951, 11(4):480-493.
    • (1951) Am J Med , vol.11 , Issue.4 , pp. 480-493
    • Barr, D.P.1    Russ, E.M.2    Eder, H.A.3
  • 8
    • 0018117095 scopus 로고
    • A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the committee of principal investigators
    • A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the committee of principal investigators. Br Heart J 1978, 40(10):1069-1118.
    • (1978) Br Heart J , vol.40 , Issue.10 , pp. 1069-1118
  • 9
    • 0016630250 scopus 로고
    • Clofibrate and niacin in coronary heart disease
    • Clofibrate and niacin in coronary heart disease. JAMA 1975, 231(4):360-381.
    • (1975) JAMA , vol.231 , Issue.4 , pp. 360-381
  • 10
    • 0023001772 scopus 로고
    • Fifteen year mortality in coronary drug project patients: long-term benefit with niacin
    • Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
    • (1986) J Am Coll Cardiol , vol.8 , pp. 1245-1255
    • Canner, P.L.1    Berge, K.G.2    Wenger, N.K.3
  • 11
    • 0018080777 scopus 로고
    • Pooling project research group: relationship of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events: final report of the pooling project
    • Pooling project research group: relationship of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chronic Dis 1978, 31:201-306.
    • (1978) J Chronic Dis , vol.31 , pp. 201-306
  • 12
    • 0017384270 scopus 로고
    • High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study
    • Gordon T., Castelli W.P., Hjortland M.C., et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977, 62:707-714.
    • (1977) Am J Med , vol.62 , pp. 707-714
    • Gordon, T.1    Castelli, W.P.2    Hjortland, M.C.3
  • 13
    • 0021349709 scopus 로고
    • The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
    • The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251(3):365-374.
    • (1984) JAMA , vol.251 , Issue.3 , pp. 365-374
  • 14
    • 0023232216 scopus 로고
    • Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
    • Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317(20):1237-1245.
    • (1987) N Engl J Med , vol.317 , Issue.20 , pp. 1237-1245
    • Frick, M.H.1    Elo, O.2    Haapa, K.3
  • 15
    • 0020025460 scopus 로고
    • Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers
    • Tobert J.A., Bell G.D., Birtwell J., et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. J Clin Invest 1982, 69(4):913-919.
    • (1982) J Clin Invest , vol.69 , Issue.4 , pp. 913-919
    • Tobert, J.A.1    Bell, G.D.2    Birtwell, J.3
  • 16
    • 0022544297 scopus 로고
    • Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia
    • Hoeg J.M., Maher M.B., Zech L.A., et al. Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. Am J Cardiol 1986, 57(11):933-939.
    • (1986) Am J Cardiol , vol.57 , Issue.11 , pp. 933-939
    • Hoeg, J.M.1    Maher, M.B.2    Zech, L.A.3
  • 17
    • 0023879688 scopus 로고
    • The lovastatin study group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia
    • The lovastatin study group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA 1988, 260(3):359-366.
    • (1988) JAMA , vol.260 , Issue.3 , pp. 359-366
  • 18
    • 0025126012 scopus 로고
    • The lovastatin study group IV. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia
    • The lovastatin study group IV. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. Am J Cardiol 1990, 66(8):22B-30B.
    • (1990) Am J Cardiol , vol.66 , Issue.8
  • 19
    • 0023761692 scopus 로고
    • Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study
    • Tikkanen M.J., Helve E., Jäättelä A., et al. Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study. Am J Cardiol 1988, 62(15):35J-43J.
    • (1988) Am J Cardiol , vol.62 , Issue.15
    • Tikkanen, M.J.1    Helve, E.2    Jäättelä, A.3
  • 20
    • 0025183769 scopus 로고
    • Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
    • Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323(19):1289-1298.
    • (1990) N Engl J Med , vol.323 , Issue.19 , pp. 1289-1298
    • Brown, G.1    Albers, J.J.2    Fisher, L.D.3
  • 21
    • 26944457749 scopus 로고    scopus 로고
    • Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes
    • Saiki A., Murano T., Watanabe F., et al. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 2005, 12(3):163-168.
    • (2005) J Atheroscler Thromb , vol.12 , Issue.3 , pp. 163-168
    • Saiki, A.1    Murano, T.2    Watanabe, F.3
  • 22
    • 0038645309 scopus 로고    scopus 로고
    • Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
    • Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003, 92(2):152-160.
    • (2003) Am J Cardiol , vol.92 , Issue.2 , pp. 152-160
    • Jones, P.H.1    Davidson, M.H.2    Stein, E.A.3
  • 23
    • 34249723258 scopus 로고    scopus 로고
    • Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages
    • Yano M., Matsumura T., Senokuchi T., et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2007, 100(10):1442-1451.
    • (2007) Circ Res , vol.100 , Issue.10 , pp. 1442-1451
    • Yano, M.1    Matsumura, T.2    Senokuchi, T.3
  • 24
    • 26844564725 scopus 로고    scopus 로고
    • The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes
    • Ray K.K., Cannon C.P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005, 46(8):1425-1433.
    • (2005) J Am Coll Cardiol , vol.46 , Issue.8 , pp. 1425-1433
    • Ray, K.K.1    Cannon, C.P.2
  • 25
    • 0027322448 scopus 로고
    • Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease
    • Brown B.G., Zhao X.Q., Sacco D.E., et al. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993, 87(6):1781-1791.
    • (1993) Circulation , vol.87 , Issue.6 , pp. 1781-1791
    • Brown, B.G.1    Zhao, X.Q.2    Sacco, D.E.3
  • 26
    • 0022620299 scopus 로고
    • Angiographic evolution of coronary artery morphology in unstable angina
    • Ambrose J.A., Winters S.L., Arora R.R., et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986, 7(3):472-478.
    • (1986) J Am Coll Cardiol , vol.7 , Issue.3 , pp. 472-478
    • Ambrose, J.A.1    Winters, S.L.2    Arora, R.R.3
  • 27
    • 19944429519 scopus 로고    scopus 로고
    • Reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
    • Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352(1):29-38.
    • (2005) N Engl J Med , vol.352 , Issue.1 , pp. 29-38
    • Nissen, S.E.1    Tuzcu, E.M.2    Schoenhagen, P.3
  • 28
    • 33947713026 scopus 로고    scopus 로고
    • Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial
    • Crouse J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297(12):1344-1353.
    • (2007) JAMA , vol.297 , Issue.12 , pp. 1344-1353
    • Crouse, J.R.1    Raichlen, J.S.2    Riley, W.A.3
  • 29
    • 66149127774 scopus 로고    scopus 로고
    • Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study
    • Bots M.L., Palmer M.K., Dogan S., et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. J Intern Med 2009, 265(6):698-707.
    • (2009) J Intern Med , vol.265 , Issue.6 , pp. 698-707
    • Bots, M.L.1    Palmer, M.K.2    Dogan, S.3
  • 30
    • 33645524176 scopus 로고    scopus 로고
    • Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial
    • Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295(13):1556-1565.
    • (2006) JAMA , vol.295 , Issue.13 , pp. 1556-1565
    • Nissen, S.E.1    Nicholls, S.J.2    Sipahi, I.3
  • 31
    • 0035916233 scopus 로고    scopus 로고
    • Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization
    • Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103(7):926-933.
    • (2001) Circulation , vol.103 , Issue.7 , pp. 926-933
    • Crisby, M.1    Nordin-Fredriksson, G.2    Shah, P.K.3
  • 32
    • 0028883828 scopus 로고
    • Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
    • Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
    • (1995) N Engl J Med , vol.333 , pp. 1301-1307
    • Shepherd, J.1    Cobbe, S.M.2    Ford, I.3
  • 33
    • 33748952489 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
    • Nakamura H., Arakawa K., Itakura H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 368(9542):1155-1163.
    • (2006) Lancet , vol.368 , Issue.9542 , pp. 1155-1163
    • Nakamura, H.1    Arakawa, K.2    Itakura, H.3
  • 34
    • 0032572086 scopus 로고    scopus 로고
    • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
    • Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279(20):1615-1622.
    • (1998) JAMA , vol.279 , Issue.20 , pp. 1615-1622
    • Downs, J.R.1    Clearfield, M.2    Weis, S.3
  • 35
    • 0028020982 scopus 로고
    • Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group
    • Furberg C.D., Adams H.P., Applegate W.B., et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994, 90(4):1679-1687.
    • (1994) Circulation , vol.90 , Issue.4 , pp. 1679-1687
    • Furberg, C.D.1    Adams, H.P.2    Applegate, W.B.3
  • 36
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
    • Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361(9364):1149-1158.
    • (2003) Lancet , vol.361 , Issue.9364 , pp. 1149-1158
    • Sever, P.S.1    Dahlöf, B.2    Poulter, N.R.3
  • 37
    • 70449707632 scopus 로고    scopus 로고
    • Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT)
    • Manisty C., Mayet J., Tapp R.J., et al. Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). Hypertension 2009, 54(5):1009-1013.
    • (2009) Hypertension , vol.54 , Issue.5 , pp. 1009-1013
    • Manisty, C.1    Mayet, J.2    Tapp, R.J.3
  • 38
    • 55949096863 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients
    • Mills E.J., Rachlis B., Wu P., et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008, 52(22):1769-1781.
    • (2008) J Am Coll Cardiol , vol.52 , Issue.22 , pp. 1769-1781
    • Mills, E.J.1    Rachlis, B.2    Wu, P.3
  • 39
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • JUPITER study group
    • Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21):2195-2207. JUPITER study group.
    • (2008) N Engl J Med , vol.359 , Issue.21 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3
  • 40
    • 78650181463 scopus 로고    scopus 로고
    • Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 10-year risk
    • [Epub ahead of print]
    • Ridker P.M., MacFayden J.G., Nordestgaard B.G., et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Circ Cardiovasc Qual Outcomes 2010, 3(5):447-452. [Epub ahead of print].
    • (2010) Circ Cardiovasc Qual Outcomes , vol.3 , Issue.5 , pp. 447-452
    • Ridker, P.M.1    MacFayden, J.G.2    Nordestgaard, B.G.3
  • 41
    • 77954210143 scopus 로고    scopus 로고
    • Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal
    • de Lorgeril M., Salen P., Abramson J., et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 2010, 170(12):1032-1036.
    • (2010) Arch Intern Med , vol.170 , Issue.12 , pp. 1032-1036
    • de Lorgeril, M.1    Salen, P.2    Abramson, J.3
  • 42
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
    • The 4S Investigators.
    • The 4S Investigators Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934):1383-1389.
    • (1994) Lancet , vol.344 , Issue.8934 , pp. 1383-1389
  • 43
    • 0342981862 scopus 로고    scopus 로고
    • The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
    • Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335(14):1001-1009.
    • (1996) N Engl J Med , vol.335 , Issue.14 , pp. 1001-1009
    • Sacks, F.M.1    Pfeffer, M.A.2    Moye, L.A.3
  • 44
    • 0032487931 scopus 로고    scopus 로고
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339(19):1349-1357.
    • (1998) N Engl J Med , vol.339 , Issue.19 , pp. 1349-1357
  • 45
    • 3142716722 scopus 로고    scopus 로고
    • Effectiveness of statin therapy in adults with coronary heart disease
    • Wilt T.J., Bloomfield H.E., MacDonald R., et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004, 164(13):1427-1436.
    • (2004) Arch Intern Med , vol.164 , Issue.13 , pp. 1427-1436
    • Wilt, T.J.1    Bloomfield, H.E.2    MacDonald, R.3
  • 46
    • 0035804846 scopus 로고    scopus 로고
    • Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial
    • Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285(13):1711-1718.
    • (2001) JAMA , vol.285 , Issue.13 , pp. 1711-1718
    • Schwartz, G.G.1    Olsson, A.G.2    Ezekowitz, M.D.3
  • 47
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
    • (2004) N Engl J Med , vol.350 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 48
    • 71649112327 scopus 로고    scopus 로고
    • Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial
    • Murphy S.A., Cannon C.P., Wiviott S.D., et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 2009, 54(25):2358-2362.
    • (2009) J Am Coll Cardiol , vol.54 , Issue.25 , pp. 2358-2362
    • Murphy, S.A.1    Cannon, C.P.2    Wiviott, S.D.3
  • 49
    • 74049109446 scopus 로고    scopus 로고
    • TNT Investigators. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial)
    • LaRosa J.C., Deedwania P.C., Shepherd J., et al. TNT Investigators. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol 2010, 105(3):283-287.
    • (2010) Am J Cardiol , vol.105 , Issue.3 , pp. 283-287
    • LaRosa, J.C.1    Deedwania, P.C.2    Shepherd, J.3
  • 50
    • 43049163859 scopus 로고    scopus 로고
    • Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery
    • Shah S.J., Waters D.D., Barter P., et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol 2008, 51(20):1938-1943.
    • (2008) J Am Coll Cardiol , vol.51 , Issue.20 , pp. 1938-1943
    • Shah, S.J.1    Waters, D.D.2    Barter, P.3
  • 51
    • 27744603499 scopus 로고    scopus 로고
    • High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
    • Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294(19):2437-2445.
    • (2005) JAMA , vol.294 , Issue.19 , pp. 2437-2445
    • Pedersen, T.R.1    Faergeman, O.2    Kastelein, J.J.3
  • 52
    • 10744228379 scopus 로고    scopus 로고
    • Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial
    • The LIPID Study Group
    • Keech A., Colquhoun D., Best J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003, 26:2713-2721. The LIPID Study Group.
    • (2003) Diabetes Care , vol.26 , pp. 2713-2721
    • Keech, A.1    Colquhoun, D.2    Best, J.3
  • 53
    • 0037840242 scopus 로고    scopus 로고
    • MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial
    • Heart Protection Study Collaborative Group
    • Collins R., Armitage J., Parish S., et al. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial. Lancet 2003, 361:2005-2016. Heart Protection Study Collaborative Group.
    • (2003) Lancet , vol.361 , pp. 2005-2016
    • Collins, R.1    Armitage, J.2    Parish, S.3
  • 54
    • 4344683381 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    • CARDS Investigators
    • Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696. CARDS Investigators.
    • (2004) Lancet , vol.364 , pp. 685-696
    • Colhoun, H.M.1    Betteridge, D.J.2    Durrington, P.N.3
  • 55
    • 33748303084 scopus 로고    scopus 로고
    • Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
    • Deedwania P., Barter P., Carmena R., et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006, 368(9539):919-928.
    • (2006) Lancet , vol.368 , Issue.9539 , pp. 919-928
    • Deedwania, P.1    Barter, P.2    Carmena, R.3
  • 56
    • 33947608774 scopus 로고    scopus 로고
    • Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions
    • Heart Protection Study Collaborative Group.
    • Heart Protection Study Collaborative Group Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007, 45(4):645-654.
    • (2007) J Vasc Surg , vol.45 , Issue.4 , pp. 645-654
  • 57
    • 0037432196 scopus 로고    scopus 로고
    • Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease
    • McDermott M.M., Guralnik J.M., Greenland P., et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003, 107(5):757-761.
    • (2003) Circulation , vol.107 , Issue.5 , pp. 757-761
    • McDermott, M.M.1    Guralnik, J.M.2    Greenland, P.3
  • 58
    • 33644598993 scopus 로고    scopus 로고
    • Statin use and functional decline in patients with and without peripheral arterial disease
    • Giri J., McDermott M.M., Greenland P., et al. Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol 2006, 47(5):998-1004.
    • (2006) J Am Coll Cardiol , vol.47 , Issue.5 , pp. 998-1004
    • Giri, J.1    McDermott, M.M.2    Greenland, P.3
  • 59
    • 0141504333 scopus 로고    scopus 로고
    • Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease
    • Mohler E.R., Hiatt W.R., Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003, 108(12):1481-1486.
    • (2003) Circulation , vol.108 , Issue.12 , pp. 1481-1486
    • Mohler, E.R.1    Hiatt, W.R.2    Creager, M.A.3
  • 60
    • 41549159287 scopus 로고    scopus 로고
    • Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study
    • Shepherd J., Kastelein J.J., Bittner V., et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008, 51(15):1448-1454.
    • (2008) J Am Coll Cardiol , vol.51 , Issue.15 , pp. 1448-1454
    • Shepherd, J.1    Kastelein, J.J.2    Bittner, V.3
  • 61
    • 38449119409 scopus 로고    scopus 로고
    • Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study
    • Shepherd J., Kastelein J.J., Bittner V., et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007, 2(6):1131-1139.
    • (2007) Clin J Am Soc Nephrol , vol.2 , Issue.6 , pp. 1131-1139
    • Shepherd, J.1    Kastelein, J.J.2    Bittner, V.3
  • 62
    • 67649426365 scopus 로고    scopus 로고
    • HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
    • CD007784
    • Navaneethan S.D., Pansini F., Perkovic V., et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009, (2). CD007784.
    • (2009) Cochrane Database Syst Rev , Issue.2
    • Navaneethan, S.D.1    Pansini, F.2    Perkovic, V.3
  • 63
    • 22344458137 scopus 로고    scopus 로고
    • Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
    • German Diabetes and Dialysis Study Investigators
    • Wanner C., Krane V., März W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353(3):238-248. German Diabetes and Dialysis Study Investigators.
    • (2005) N Engl J Med , vol.353 , Issue.3 , pp. 238-248
    • Wanner, C.1    Krane, V.2    März, W.3
  • 64
    • 63849163945 scopus 로고    scopus 로고
    • Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
    • AURORA Study Group
    • Fellström B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360(14):1395-1407. AURORA Study Group.
    • (2009) N Engl J Med , vol.360 , Issue.14 , pp. 1395-1407
    • Fellström, B.C.1    Jardine, A.G.2    Schmieder, R.E.3
  • 65
    • 3142729178 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines
    • The Coordinating Committee of the National Cholesterol Education Program
    • Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004, 110:227-239. The Coordinating Committee of the National Cholesterol Education Program.
    • (2004) Circulation , vol.110 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3
  • 66
    • 33744982042 scopus 로고    scopus 로고
    • AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update
    • Smith S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006, 113:2363-2372.
    • (2006) Circulation , vol.113 , pp. 2363-2372
    • Smith, S.C.1    Allen, J.2    Blair, S.N.3
  • 67
    • 34547655744 scopus 로고    scopus 로고
    • ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarctio
    • Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007, 50:e1-e157.
    • (2007) J Am Coll Cardiol , vol.50
    • Anderson, J.L.1    Adams, C.D.2    Antman, E.M.3
  • 68
    • 33645737200 scopus 로고    scopus 로고
    • Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American heart association/American stroke association council on stroke: co-sponsored by the council on cardiovascular radiology and intervention: the American academy of neurology affirms the value of this guideline
    • Sacco R.L., Adams R., Albers G., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American heart association/American stroke association council on stroke: co-sponsored by the council on cardiovascular radiology and intervention: the American academy of neurology affirms the value of this guideline. Circulation 2006, 113(10):e409-e449.
    • (2006) Circulation , vol.113 , Issue.10
    • Sacco, R.L.1    Adams, R.2    Albers, G.3
  • 69
    • 40249120466 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2008
    • American Diabetes Association.
    • American Diabetes Association Standards of medical care in diabetes-2008. Diabetes Care 2008, 31(Suppl 1):S12-S54.
    • (2008) Diabetes Care , vol.31 , Issue.SUPPL. 1
  • 70
    • 0037379751 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease
    • National Kidney Foundation
    • National Kidney Foundation K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003, 41(4 Suppl 3):S1-S2.
    • (2003) Am J Kidney Dis , vol.41 , Issue.4 SUPPL. 3
  • 71
    • 42549154342 scopus 로고    scopus 로고
    • Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia
    • Armitage J. Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia. Heart 2008, 94(5):643-645.
    • (2008) Heart , vol.94 , Issue.5 , pp. 643-645
    • Armitage, J.1
  • 72
    • 41649107358 scopus 로고    scopus 로고
    • ENHANCE investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia
    • Kastelein J.J., Akdim F., Stroes E.S., et al. ENHANCE investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358(14):1431-1443.
    • (2008) N Engl J Med , vol.358 , Issue.14 , pp. 1431-1443
    • Kastelein, J.J.1    Akdim, F.2    Stroes, E.S.3
  • 73
    • 72049129430 scopus 로고    scopus 로고
    • Extended-release niacin or ezetimibe and carotid intima-media thickness
    • Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361(22):2113-2122.
    • (2009) N Engl J Med , vol.361 , Issue.22 , pp. 2113-2122
    • Taylor, A.J.1    Villines, T.C.2    Stanek, E.J.3
  • 74
    • 52649120889 scopus 로고    scopus 로고
    • Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
    • Rossebø A.B., Pedersen T.R., Boman K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359(13):1343-1356.
    • (2008) N Engl J Med , vol.359 , Issue.13 , pp. 1343-1356
    • Rossebø, A.B.1    Pedersen, T.R.2    Boman, K.3
  • 75
    • 50949102416 scopus 로고    scopus 로고
    • Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
    • Cannon C.P., Giugliano R.P., Blazing M.A., et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008, 156(5):826-832.
    • (2008) Am Heart J , vol.156 , Issue.5 , pp. 826-832
    • Cannon, C.P.1    Giugliano, R.P.2    Blazing, M.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.